Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | ROS1 | P08922 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | MARK3 | P27448 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376635 | 0.94 | PIK3CD (0.54) | MAP3K11TNIKPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12343087 | 0.94 | EGLN1 (0.45) | MAP3K11EGLN1TNIKPIK3CDPIK3CA | |
| SCHEMBL12342842 | 0.92 | JAK2 (0.55) | MAP3K11PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12343096 | 0.92 | MAP3K11 (0.47) | MAP3K11EGLN1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3374236 | 0.91 | ABL1 (0.51) | MAP3K11PIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL12343289 | 0.91 | ABL1 (0.47) | MAP3K11KCNH2CDK4CCND1NPC1 | |
| SCHEMBL3374205 | 0.91 | SLC6A7 (0.56) | MAP3K11PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12343250 | 0.91 | BMPR1B (0.50) | MAP3K11PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12343301 | 0.90 | HPGD (0.47) | MAP3K11KCNH2CDK4CCND1NPC1 | |
| SCHEMBL12343275 | 0.90 | MAP3K11 (0.47) | MAP3K11EGLN1TNIKPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7829558-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829558-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829558-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2239262-A2 | Fused ring heterocycle kinase modulators | SGX Pharmaceuticals, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| EP-2239262-A2 | Fused ring heterocycle kinase modulators | SGX Pharmaceuticals, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-7452993-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452993-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1778687-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | STRUCTURAL GENOMIX, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2006015124-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | MAP3K20, TTK, MAP3K19 | MAP3K11 26/4885EGLN1 2462/4885TNIK 119/4885 |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | MAP3K11 26/4885EGLN1 2462/4885TNIK 119/4885 |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | MAP3K11 26/4885EGLN1 2462/4885TNIK 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.